We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ixico Plc | LSE:IXI | London | Ordinary Share | GB00BFXR4C20 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 11.50 | 0.00 | 08:00:02 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 11.00 | 12.00 | 11.50 | 11.50 | 11.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 11.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 16/12/2024 | 07:00 | UK RNS | IXICO plc Commercial agreement with PETNET Solutions Inc |
| 10/12/2024 | 15:34 | ALNC |  EARNINGS AND TRADING: Dianomi trading in line; Solid State profit dips |
| 10/12/2024 | 07:00 | UK RNS | IXICO plc Contract Win |
| 04/12/2024 | 11:46 | ALNC | Ixico loss widens as contract wins slow; shares plummet |
| 04/12/2024 | 11:35 | UK RNS | IXICO plc Share Option Award & PDMR Dealings |
| 04/12/2024 | 07:00 | UK RNS | IXICO plc Financial Results for year ended 30 September 2024 |
| 25/11/2024 | 07:00 | UK RNS | IXICO plc Notice of Results and Investor Presentation |
| 31/10/2024 | 07:00 | UK RNS | IXICO plc Share Option Awards & PDMR Dealing |
| 30/10/2024 | 16:50 | UK RNS | IXICO plc Holding(s) in Company |
| 29/10/2024 | 16:00 | UK RNS | IXICO plc Holding(s) in Company |
Ixico (IXI) Share Charts1 Year Ixico Chart |
|
1 Month Ixico Chart |
Intraday Ixico Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 28/5/2024 10:55 by citys2874 good buying pressure coming in today mms ready to lift share price higher |
Posted at 25/5/2024 11:05 by 40 fathoms Contract delays in the CNS space are very much a fact and not IXI specific, you can see this in the outlook statements of their peers.IXI have really backed themselves in to corner with their reckless spending on just about everything over the past 5 years. insane salaries, undisciplined R&D spending, overstaffing, a useless board. This is now coming back to plague them. Even if they win significant numbers of large contracts in the next 6 months they do not have sufficient working capital to be certain they can execute. This will also impact sponsors confidence to contract with them. They need an additional 2-3 million cash to correct this situation. In truth the best outcome for existing shareholders is for the board to conduct a process and sell the business. Of course they won't do that, they will tap the market for cash equivalent to 60% to 80% of the current market cap. Almost doubling the share count in the process. On the plus side they have many on the register that can stand their round, on the negative side any CR does not necessarily, permanently, fix the problem. One point in the IMC prevention where I think they are being a bit disingenuous is with respect to the balance of their contract book. They have pointed to the shift from large late stage trials to smaller early stage trials. While it is true this reduces their risk to any individual trial descope or cancellation, what they have not mentioned is the huge failure rate for early stage CNS trials. Although it is improving, it has historically been about 95% for phase I CNS trials. So having early stage trials can lead to large later stage trials, the probability of any individual trial progressing to a later stage is very, very low. |
Posted at 27/1/2024 12:35 by 40 fathoms Well Giulio is going, it was clear all the fight had gone out of him so it is not a huge surprise as he has not been very effective but has been very, very expensive. It is going to take a year for him to leave and there will have to overlap with another expensive (but hopefully less so) CEO, so there will be double costs for a while.CFO also needs to be replaced with one that costs half as much and then you would have clean foundations and things can start to look a lot better. Also, unless they are able to sign some large, new, contracts and or cut their R&D spend very soon then they are going to need more cash. With the right CEO and a much less ambitions strategy it would not be hard to get to a position where it is making a sustanible EBIT of GBP 2 or GBP 3 million per year. That is worth a share price of 50p in my view, provided they do not increase the share count. They also need to give up on AD and ARIA as they are not in the race. Double down on Huntingdon's and pick up the focus on some of the other less competitive CNS indications. If we see this or a similar strategy put in place then I am a buyer. If this does not happen this is going to bump around between 8p and 15p for as far as the eye can see. |
Posted at 26/1/2024 04:22 by up4itt The selling is attributable to the fact that I had just bought in prior to the drop in the share price. The correlation seldom fails. |
Posted at 08/12/2023 11:02 by jimtech Guilio was obviously frustrated with the "harsh" lowly company valuation.But then there is not much to get excited about if they are expecting a flat 2024 so share price may well sink further. I thought the fundraising comments were theoretical but you are right, as you point out, they were not dismissed out of hand. |
Posted at 23/6/2023 11:27 by 40 fathoms @Jane Deer.Any market surveillance in AD would be to identify ARIA H and ARIA E in patients (not as a diagnostic) that are given monoclonal antibodies that clear Amyloid Beta. The PDUFA date for a full approval of Lecanamab is 6th July and at that point we will know, if approved, what requirements the FDA will impose for market surveillance. If they were to win anything in the near term, this is the opportunity, particularly as they have provided the Assessa platform for progressive multifocal leukoencephalopathy (PML)in conjunction with Biogen, who is also the co-developer of Lecanamab. So you would think this would represent the most likely live opportunity. That said Eisai and Biogen have been preparing for this approval and subsequent role out for years now and have put in place the infrastructure to support and monitor this rollout. I would be very surprised indeed, if now at this late stage, they announce something exclusive with Ixico for Lecanamab. As you might be aware, last year Adhuelm also a Biogen AD Thereaputic, was approved by the FDA last year. Although it has been a complete disaster commercially, there was post market surveillance requirements imposed by the FDA and I note that their was no post market surveillance contract for Ixico. There is a possibility they could win something with Lilly for Donanemab, which will likely be approved and rolled out 1H next year. However, as with Biogen/Eisai, given the scale of preparation that goes in to a drug launch of this type, I think we would know by now if they were likely to gain a contract here. My feeling is in the longer run they might pick up some work in this regard by contracting with individual hospitals or health systems. However, this is likely 2 or more years away and it will be slow to build, in particular as they have no healthcare sales network. While a rabbit could be pulled from the hat, I think the reality is that the next 12 to 18 months are going to be difficult for Ixico. If they can shepherd their cash then there is a good possibility of salvation after that. If they cannot, the board and the C suite are crazily paid, then they are going to need to raise a decent (in comparison to market cap) amount of cash with all of the share price pain that entails. |
Posted at 10/5/2023 07:29 by halfpenny Now IXI have a strong platform with cash in the bank, AI products and a strong order book for 2023 and great outlook for 2024.IXI with strong AI products being released puts them ahead of the market. Investors now circulating IXI at these levels. Future looking great for IXI. |
Posted at 24/4/2023 11:45 by halfpenny IXI now likely being pursued by a couple on investors who missed out on Medica Group Plc today.Investors now circulating IXI at these levels. Only large deals with a share price above 33p can keep them away. Future looking great for IXI. |
Posted at 04/4/2023 07:28 by halfpenny Another Order for IXI so expect plenty more in the pipeline. Takeover target at these levels so needs rapid orders. Interesting times ahead so got more at these levels.IXI have a huge increasing interest of its AI Products , is this when the company orders and sales pipeline grows quickly. Maybe a Takeover still on the cards as IXICO price levels are attractive at the current levels. IXI future is very bright so get ready for dramatic price increases ahead. Following yesterday RNS Expect further RNS soon on great Deals. |
Posted at 21/4/2022 06:33 by tomboyb IXICO plc New Contract Win21/04/2022 7:00am UK Regulatory (RNS & others) Ixico (LSE:IXI) Intraday Stock Chart Thursday 21 April 2022 Click Here for more Ixico Charts. TIDMIXI RNS Number : 8126I IXICO plc 21 April 2022 21 April 2022 IXICO plc ("IXICO" or the "Company") Contract award with a new client for a Huntington's Disease ('HD') trial worth circa GBP800,000 IXICO plc (AIM: IXI), the neuroimaging Contract Research Organisation (CRO) delivering advanced AI analytical insights in neuroscience, is pleased to announce it has been selected by a new client to support its global prospective observational study to assess participants for the early detection of HD. HD is a rare, inherited disease that causes the progressive breakdown of nerve cells in the brain affecting movement, mood and thinking abilities. The new client is a biotech company specialized in gene therapy for neurodegenerative and other genetic diseases. IXICO will provide a range of its imaging CRO and advanced analytics services across approximately 2.5 years. Having combined AI imaging biomarker analysis across many HD trials, together with centralised CRO services, IXICO is continuously enhancing its validated disease-optimised advanced analytics technology for this indication. This new contract follows our recent presentation on our new deep learning-based platform, IXIQ.Ai, at the Annual HD Therapeutics Conference in Palm Springs, a technology which IXICO will be applying to this trial. This, together with the ability to deliver its services through our proprietary TrialTracker imaging data management platform, makes IXICO the clear partner of choice for this study. Giulio Cerroni, Chief Executive Officer of IXICO, commented : " With no current cure for Huntington's, nor interventions that slow disease progression, HD is a devastating rare neurological condition with significant unmet medical needs. We are delighted to further extend our client base and support identifying new insights into this challenging rare neurodegenerative disease. We are committed to ensuring that our validated machine learning AI data analytics, combined with the quality assurance of our TrialTracker platform, enable clients to unlock new insights into disease progression and drug development." For further information please contact: |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
